{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:43:00Z","timestamp":1787010180081,"version":"build-2736575974"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:p>Esketamine, the S-enantiomer of ketamine, has emerged as a rapid-acting antidepressant with unique mechanisms. This narrative review synthesizes current evidence on its clinical applications, safety, and regulatory status based on peer-reviewed literature published between January 2000 and March 2024, searched in PubMed, Web of Science, and the Cochrane Library. Esketamine exerts its effects primarily through noncompetitive antagonism of N-methyl-D-aspartate receptors, leading to rapid modulation of glutamatergic signaling and neuroplasticity. In anesthesia, it provides effective sedation with minimal respiratory depression. In psychiatry, intravenous and intranasal esketamine have demonstrated rapid antidepressant effects in treatment-resistant depression, with response rates of 50% to 70% within 24 hours. However, long-term safety data remain limited, and concerns persist regarding dissociative symptoms, cognitive impairment, and abuse potential. Regulatory approvals vary: the Food and Drug Administration approved intranasal esketamine for treatment-resistant depression in 2019, while European and Asian countries have adopted differing restrictions. Esketamine represents a paradigm shift in depression treatment, but its use requires careful patient selection, monitoring, and risk management. Future research should focus on head-to-head comparisons with other rapid-acting interventions, long-term outcomes, and integration into stepped-care models.<\/jats:p>","DOI":"10.1097\/md.0000000000048570","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:00:42Z","timestamp":1777629642000},"page":"e48570","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A comprehensive review of the clinical progress of esketamine: From anesthesia to antidepressant therapy"],"prefix":"10.1097","volume":"105","author":[{"given":"Hai-lin","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Guizhou Medical University, Guiyang, Guizhou, China"},{"name":"Department of Guizhou Provincial People\u2019s Hospital, Guiyang, Guizhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-zhou","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Guizhou Medical University, Guiyang, Guizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9782-1726","authenticated-orcid":false,"given":"Ping-xia","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Guizhou Medical University, Guiyang, Guizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260622","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1111\/cts.13572","article-title":"Remimazolam versus propofol in combination with esketamine for surgical abortion: a double-blind randomized controlled trial.","volume":"16","author":"Linli","year":"2023","journal-title":"Clin Transl Sci"},{"key":"R2-20260622","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/13696998.2023.2208993","article-title":"Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.","volume":"26","author":"Maryia","year":"2023","journal-title":"J Med Econ"},{"key":"R3-20260622","first-page":"11","article-title":"Reporting of harms in clinical trials of esketamine in depression: a systematic review.","volume":"53","author":"Tanguy","year":"2023","journal-title":"Psychol Med"},{"key":"R4-20260622","doi-asserted-by":"crossref","first-page":"204.doi","DOI":"10.1186\/s12871-023-02167-0","article-title":"Efficacy and safety of esketamine for sedation among patients undergoing gastrointestinal endoscopy: a systematic review and meta-analysis.","volume":"23","author":"Xianghong","year":"2023","journal-title":"BMC Anesthesiol"},{"key":"R5-20260622","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant.","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol Psychiatry"},{"key":"R6-20260622","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp1903305","article-title":"Esketamine for treatment-resistant depression - first FDA-approved antidepressant in a new class.","volume":"381","author":"Kim","year":"2019","journal-title":"N Engl J Med"},{"key":"R7-20260622","first-page":"e37833","article-title":"Clinical effectiveness of N-methyl-D-aspartate (NMDA) receptor antagonists in adult obsessive-compulsive disorder (OCD) treatment: a systematic review.","volume":"15","author":"Ferguson","year":"2023","journal-title":"Cureus"},{"key":"R8-20260622","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.bja.2018.02.021","article-title":"Esketamine counters opioid-induced respiratory depression.","volume":"120","author":"Jonkman","year":"2018","journal-title":"Br J Anaesth"},{"key":"R9-20260622","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00128-024-03883-0","article-title":"Effects of new psychoactive substance esketamine on behaviors and transcription of genes in dopamine and GABA pathways in Zebrafish Larvae.","volume":"112","author":"Li","year":"2024","journal-title":"Bull Environ Contam Toxicol"},{"key":"R10-20260622","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bdi.13375","article-title":"Esketamine nasal spray in severe bipolar depression with borderline personality disorder and history of multiple substance abuse: a case report.","volume":"25","author":"de Filippis","year":"2023","journal-title":"Bipolar Disord"},{"key":"R11-20260622","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.bja.2023.10.038","article-title":"Esketamine accelerates emergence from isoflurane general anaesthesia by activating the paraventricular thalamus glutamatergic neurones in mice.","volume":"132","author":"Duan","year":"2024","journal-title":"Br J Anaesth"},{"key":"R12-20260622","first-page":"18","article-title":"Effects of esketamine combined with propofol for hysteroscopy anesthesia on patient hemodynamics and adverse reactions.","volume":"30","author":"Wang","year":"2024","journal-title":"Altern Ther Health Med"},{"key":"R13-20260622","doi-asserted-by":"crossref","first-page":"548","DOI":"10.52312\/jdrs.2023.997","article-title":"A subanesthetic dose of esketamine combined with hip peripheral nerve block has good sedative and analgesic effects in elderly patients undergoing total hip arthroplasty: a randomized-controlled trial.","volume":"34","author":"Dai","year":"2023","journal-title":"Jt Dis Relat Surg"},{"key":"R14-20260622","doi-asserted-by":"crossref","first-page":"137","DOI":"10.26689\/jcnr.v7i6.5621","article-title":"The ED50 of remazolam toluenesulfonate combined with a subthreshold dose of esketamine for inhibiting cardiovascular response to tracheal intubation in elderly patients.","volume":"7","author":"Zhao","year":"2023","journal-title":"JCNR"},{"key":"R15-20260622","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1186\/s12871-023-02357-w","article-title":"The ED50 and ED95 of esketamine for preventing early postoperative pain in patients undergoing laparoscopic cholecystectomy: a prospective, double-blinded trial.","volume":"23","author":"Xu","year":"2023","journal-title":"BMC Anesthesiol"},{"key":"R16-20260622","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/EBP.0000000000001549","article-title":"Does a course of cognitive behavioral therapy reduce the recurrence of depression in patients on antidepressants?","volume":"25","author":"Carlson","year":"2022","journal-title":"Evid Based Pract"},{"key":"R17-20260622","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial.","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"R18-20260622","doi-asserted-by":"crossref","first-page":"19m12891","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2).","volume":"81","author":"Wajs","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"R19-20260622","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"R20-20260622","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","article-title":"Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study).","volume":"319","author":"Martinotti","year":"2022","journal-title":"J Affect Disord"},{"key":"R21-20260622","doi-asserted-by":"crossref","first-page":"22m14548","DOI":"10.4088\/JCP.22m14548","article-title":"Comparative effectiveness of intravenous ketamine and intranasal esketamine in clinical practice among patients with treatment-refractory depression: an observational study.","volume":"84","author":"Singh","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"R22-20260622","first-page":"e53987","article-title":"Exploring esketamine\u2019s therapeutic outcomes as an FDA-designated breakthrough for treatment-resistant depression and major depressive disorder with suicidal intent: a narrative review.","volume":"16","author":"Kumari","year":"2024","journal-title":"Cureus"},{"key":"R23-20260622","first-page":"802","article-title":"Comparative efficacy and tolerability of esketamine in treatment-resistant depression: a systematic review and network meta-analysis.","volume":"282","author":"Papadimitropoulou","year":"2021","journal-title":"J Affect Disord"},{"key":"R24-20260622","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1).","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"key":"R25-20260622","first-page":"236","article-title":"Esketamine and ketamine for treatment-resistant depression: a systematic review and network meta-analysis.","volume":"316","author":"Hock","year":"2022","journal-title":"J Affect Disord"},{"key":"R26-20260622","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1055\/a-2058-9010","article-title":"Effects of anesthesia changes during maintenance ECT: a longitudinal comparison of seizure quality under anesthesia using propofol\/esketamine versus methohexital.","volume":"56","author":"Methfessel","year":"2023","journal-title":"Pharmacopsychiatry"},{"key":"R27-20260622","first-page":"1071","article-title":"Acute and persistent adverse effects of ketamine and esketamine in the treatment of depression: a systematic review and meta-analysis.","volume":"36","author":"Smith-Apeldoorn","year":"2022","journal-title":"J Psychopharmacol"},{"key":"R28-20260622","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3.","volume":"28","author":"Ochs-Ross","year":"2020","journal-title":"Am J Geriatr Psychiatry"},{"key":"R29-20260622","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41398-020-00897-0","article-title":"A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated-dose intranasal esketamine in treatment-resistant depression.","volume":"10","author":"Shiroma","year":"2020","journal-title":"Transl Psychiatry"},{"key":"R30-20260622","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1017\/S2045796019000751","article-title":"Esketamine for treatment resistant depression: a trick of smoke and mirrors?","volume":"29","author":"Gastaldon","year":"2019","journal-title":"Epidemiol Psychiatr Sci"},{"key":"R31-20260622","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/jcph.2233","article-title":"The impact of sedative hypnotic drugs on hallucinated sexual assault or sexual fantasies involving health professionals: a systematic review.","volume":"63","author":"White","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"R32-20260622","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1192\/bjp.bp.115.165498","article-title":"Oral ketamine for the treatment of pain and treatment-resistant depression\u2020.","volume":"208","author":"Schoevers","year":"2016","journal-title":"Br J Psychiatry"},{"key":"R33-20260622","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation.","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am J Psychiatry"},{"key":"R34-20260622","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression.","volume":"173","author":"Singh","year":"2016","journal-title":"Am J Psychiatry"},{"key":"R35-20260622","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A consensus statement on the use of ketamine in the treatment of mood disorders.","volume":"74","author":"Sanacora","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"R38-20260622","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/07067437241245384","article-title":"Canadian network for mood and anxiety treatments (CANMAT) 2023 update on clinical guidelines for the management of major depressive disorder in adults.","volume":"69","author":"Lam","year":"2024","journal-title":"Can J Psychiatry"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T09:09:20Z","timestamp":1782119360000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":36,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048570","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"2024-07-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}